Title |
Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer
|
---|---|
Published in |
Molecular Medicine, November 2012
|
DOI | 10.2119/molmed.2012.00302 |
Pubmed ID | |
Authors |
Myra F. Barginear, Veena John, Daniel R. Budman |
Abstract |
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Although trastuzumab is a very active agent in HER2-overexpressing breast cancer, the majority of patients with metastatic HER2-overexpressing breast cancer who initially respond to trastuzumab develop resistance within 1 year of initiation of treatment and, in the adjuvant setting, progress despite trastuzumab-based therapy. The antibody-drug conjugate trastuzumab-DM1 (T-DM1) was designed to combine the biological activity of trastuzumab with the targeted delivery of a highly potent antimicrotubule agent, DM1 (N-methyl-N-[3-mercapto-1-oxopropyl]-l-alanine ester of maytansinol), a maytansine derivative, to HER2-overexpressing breast cancer cells. T-DM1 is the first antibody-drug conjugate with a nonreducible thioether linker in clinical trials. Phase I and II clinical trials of T-DM1 as a single agent and in combination with paclitaxel, docetaxel and pertuzumab have shown clinical activity and a favorable safety profile in patients with HER2-positive metastatic breast cancer. Two randomized phase III trials of T-DM1 are awaiting final results; the EMILIA trial is evaluating T-DM1 compared with lapatinib plus capecitabine, and early positive results have been reported. The MARIANNE trial is evaluating T-DM1 plus placebo versus T-DM1 plus pertuzumab versus trastuzumab plus a taxane. Here, we summarize evidence from clinical studies and discuss the potential clinical implications of T-DM1. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Ecuador | 1 | <1% |
France | 1 | <1% |
Unknown | 109 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 25 | 22% |
Other | 14 | 13% |
Student > Ph. D. Student | 14 | 13% |
Student > Master | 14 | 13% |
Student > Bachelor | 11 | 10% |
Other | 16 | 14% |
Unknown | 18 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 22% |
Agricultural and Biological Sciences | 20 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 12 | 11% |
Biochemistry, Genetics and Molecular Biology | 9 | 8% |
Chemistry | 7 | 6% |
Other | 15 | 13% |
Unknown | 24 | 21% |